Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

TransMedics (TMDX) Shares Outstanding (Diluted Average) (2020 - 2024)

Historic Shares Outstanding (Diluted Average) for TransMedics (TMDX) over the last 5 years, with Q3 2024 value amounting to $35.7 million.

  • TransMedics' Shares Outstanding (Diluted Average) rose 941.28% to $35.7 million in Q3 2024 from the same period last year, while for Sep 2024 it was $35.7 million, marking a year-over-year increase of 941.28%. This contributed to the annual value of $32.5 million for FY2023, which is 1001.72% up from last year.
  • According to the latest figures from Q3 2024, TransMedics' Shares Outstanding (Diluted Average) is $35.7 million, which was up 941.28% from $35.3 million recorded in Q2 2024.
  • In the past 5 years, TransMedics' Shares Outstanding (Diluted Average) ranged from a high of $35.7 million in Q3 2024 and a low of $21.2 million during Q1 2020
  • Its 5-year average for Shares Outstanding (Diluted Average) is $29.4 million, with a median of $28.0 million in 2022.
  • As far as peak fluctuations go, TransMedics' Shares Outstanding (Diluted Average) surged by 2896.47% in 2021, and later surged by 131.37% in 2022.
  • Over the past 5 years, TransMedics' Shares Outstanding (Diluted Average) (Quarter) stood at $24.7 million in 2020, then grew by 11.8% to $27.6 million in 2021, then grew by 7.02% to $29.6 million in 2022, then grew by 10.02% to $32.5 million in 2023, then increased by 9.74% to $35.7 million in 2024.
  • Its last three reported values are $35.7 million in Q3 2024, $35.3 million for Q2 2024, and $34.7 million during Q1 2024.